These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 31051019)

  • 1. Pharmacogenomics in dermatology: tools for understanding gene-drug associations.
    Daneshjou R; Huddart R; Klein TE; Altman RB
    Semin Cutan Med Surg; 2019 Mar; 38(1):E19-E24. PubMed ID: 31051019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics/updated for precision medicine in dermatology.
    Do LHD; Maibach H
    J Dermatolog Treat; 2019 Jun; 30(4):410-413. PubMed ID: 30238807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in dermatology: Taking patient treatment to the next level.
    Schweitzer J; Maibach H
    J Dermatolog Treat; 2015 Feb; 26(1):94-6. PubMed ID: 24552417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics: Precision Medicine and Drug Response.
    Weinshilboum RM; Wang L
    Mayo Clin Proc; 2017 Nov; 92(11):1711-1722. PubMed ID: 29101939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy.
    Pincelli C; Pignatti M; Borroni RG
    Exp Dermatol; 2009 Apr; 18(4):337-49. PubMed ID: 19348000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics and individualized medicine: translating science into practice.
    Crews KR; Hicks JK; Pui CH; Relling MV; Evans WE
    Clin Pharmacol Ther; 2012 Oct; 92(4):467-75. PubMed ID: 22948889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.
    Alessandrini M; Chaudhry M; Dodgen TM; Pepper MS
    OMICS; 2016 Oct; 20(10):593-603. PubMed ID: 27643672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics, pharmacogenomics, and individualized medicine.
    Ma Q; Lu AY
    Pharmacol Rev; 2011 Jun; 63(2):437-59. PubMed ID: 21436344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia.
    Koutsilieri S; Tzioufa F; Sismanoglou DC; Patrinos GP
    Pharmacol Res; 2020 Mar; 153():104590. PubMed ID: 31830522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics: Principles and Relevance to Oncology Nursing
.
    Dodson CH
    Clin J Oncol Nurs; 2017 Dec; 21(6):739-745. PubMed ID: 29149126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
    La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
    Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics: historical perspective and current status.
    Charlab R; Zhang L
    Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine in Oncology Pharmacy Practice.
    Saadeh C; Bright D; Rustem D
    Acta Med Acad; 2019 Apr; 48(1):90-104. PubMed ID: 31264437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
    Hoffman JM; Dunnenberger HM; Kevin Hicks J; Caudle KE; Whirl Carrillo M; Freimuth RR; Williams MS; Klein TE; Peterson JF
    J Am Med Inform Assoc; 2016 Jul; 23(4):796-801. PubMed ID: 27026620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine.
    Abad-Santos F; Aliño SF; Borobia AM; García-Martín E; Gassó P; Maroñas O; Agúndez JAG
    Pharmacol Res; 2024 Feb; 200():107061. PubMed ID: 38199278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology.
    Dalle S; Thomas L; Shear NH
    Int J Dermatol; 2011 Jan; 50(1):114-8. PubMed ID: 21182511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Off-label use].
    Fritz K; Augustin M; John SM
    Hautarzt; 2013 Oct; 64(10):727. PubMed ID: 24150819
    [No Abstract]   [Full Text] [Related]  

  • 19. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward.
    Caudle KE; Keeling NJ; Klein TE; Whirl-Carrillo M; Pratt VM; Hoffman JM
    Pharmacogenomics; 2018 Jul; 19(10):847-860. PubMed ID: 29914287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating pharmacogenomics into electronic health records with clinical decision support.
    Hicks JK; Dunnenberger HM; Gumpper KF; Haidar CE; Hoffman JM
    Am J Health Syst Pharm; 2016 Dec; 73(23):1967-1976. PubMed ID: 27864204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.